Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Small Cell Lung Carcinoma 3 Neoplasm Metastasis 2 Nasopharyngeal Carcinoma 2 Colorectal Neoplasms 2 Breast Neoplasms 2 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Peritoneal Neoplasms 1 Osteosarcoma 1 Liver, Cancer of, Primary Resectable 1 Hepatocellular Carcinoma Resectable 1 Head and Neck Neoplasms 1 Esophageal Neoplasms 1 Carcinoma, Hepatocellular 1 Advanced Gastric Cancer 1 Acute Toxic Effects 1

Interventions

Sorafenib 131 lenvatinib 115 Bevacizumab 88 Radiosurgery 69 atezolizumab 55 sintilimab 54 Nivolumab 51 durvalumab 43 Hepatectomy 43 Fluorouracil 42 apatinib 41 Oxaliplatin 41 camrelizumab 38 Radiofrequency Ablation 38 pembrolizumab 36 Radiotherapy 36 tislelizumab 35 Leucovorin 31 Magnetic Resonance Spectroscopy 30 Immune Checkpoint Inhibitors 28 Doxorubicin 28 Folfox protocol 26 tremelimumab 25 regorafenib 25 Cisplatin 20 spartalizumab 19 donafenib 19 Gemcitabine 19 Cyclophosphamide 19 toripalimab 18

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Carcinoma, Hepatocellular × lobaplatin × Clear all

NCT02301091 2016-04-14

CORTT

Sun Yat-sen University

Phase 3 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡